Roche shares drop on side effects result in early-stage obesity pill trial
Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial.
Roche Obesity Pill Study: What Are the Side Effects?
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Roche shares slip on obesity drug trial side effects
Shares of Roche (SIX:RO) fell on Thursday following reports from an early-stage trial of an obesity medication, which showed a high rate of temporary side effects. At 4:44 am (0844 GMT), Roche was trading 4% lower at
Roche says early-stage obesity pill results were based on just six patients
Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
Roche Shares Drop on Concern About Obesity Pill Side Effects
Roche Holding AG’s shares slid the most in more than a month after its closely-watched experimental obesity pill was tied to side effects, raising questions about the drugmaker’s competitiveness in the hottest new pharmaceutical market.
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...
BioSpace3d
Roche’s Obesity Pill Candidate Hit With Safety Concerns Despite Strong Efficacy Data
When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...
Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data
Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects
Roche’s stock fell after new data from an early-stage clinical trial of its closely watched oral weight-loss drug candidate ...
devdiscourse4d
Roche's Weight Loss Pill: Promising Early Results with Caveats
Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...
Yahoo Finance3d
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, ...
The Obesity Treatment Boom: Is This Only The Beginning?
The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...
FierceBiotech4d
‘The trajectory is encouraging.’ Roche hopes obesity drug will show 25% weight loss one day
Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...
Why Roche Holdings Stock Withered on Wednesday
For the second trading session in less than a week, Roche Holding ( RHHBY -6.02%) stock really took it on the chin Wednesday.